Microtubule-binding agents: a dynamic field of cancer therapeutics

被引:1418
作者
Dumontet, Charles [1 ,2 ]
Jordan, Mary Ann [3 ,4 ]
机构
[1] Fac Rockefeller, INSERM 590, F-69008 Lyon, France
[2] Univ Lyon 1, ISPB, F-69003 Lyon, France
[3] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA
[4] Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA
关键词
CELL LUNG-CANCER; PHASE-I TRIAL; METASTATIC BREAST-CANCER; ADVANCED SOLID TUMORS; III BETA-TUBULIN; COMBRETASTATIN A4 PHOSPHATE; VASCULAR-TARGETING AGENT; ADMINISTERED INDIBULIN D-24851; RESISTANCE-ASSOCIATED PROTEIN; REFRACTORY PROSTATE-CANCER;
D O I
10.1038/nrd3253
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumour cells. Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer. The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties. In the current search for novel microtubule-binding agents, enhanced tumour specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives.
引用
收藏
页码:790 / 803
页数:14
相关论文
共 217 条
[51]   Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study [J].
De Geest, Koen ;
Blessing, John A. ;
Morris, Robert T. ;
Yamada, S. Diane ;
Monk, Bradley J. ;
Zweizig, Susan L. ;
Matei, Daniela ;
Muller, Carolyn Y. ;
Richards, William E. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :149-153
[52]  
Debernardis D, 1997, CANCER RES, V57, P870
[53]  
DELEMO, 2008, CHEM-EUR J, V14, P11092
[54]   AVE8062: a new combretastatin derivative vascular disrupting agent [J].
Delmonte, Angelo ;
Sessa, Cristiana .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (10) :1541-1548
[55]   Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy [J].
Dieras, V. ;
Limentani, S. ;
Romieu, G. ;
Tubiana-Hulin, M. ;
Lortholary, A. ;
Kaufman, P. ;
Girre, V. ;
Besenval, M. ;
Valero, V. .
ANNALS OF ONCOLOGY, 2008, 19 (07) :1255-1260
[56]  
Dimitroulis J, 2005, ONCOL REP, V13, P923
[57]  
Don S, 2004, MOL CANCER THER, V3, P1137
[58]   Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies [J].
Dumontet, Charles ;
Jordan, Mary Ann ;
Lee, Francis F. Y. .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (01) :17-25
[59]   Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer [J].
Edelman, MJ ;
Gandara, DR ;
Hausner, P ;
Israel, V ;
Thornton, D ;
DeSanto, J ;
Doyle, LA .
LUNG CANCER, 2003, 39 (02) :197-199
[60]   The hematopoietic-specific β1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression [J].
Escuin, Daniel ;
Burke, Patricia A. ;
McMahon-Tobin, Grainne ;
Hembrough, Todd ;
Wang, Yuefang ;
Alcaraz, Ana A. ;
Javier Leandro-Garcia, Luis ;
Rodriguez-Antona, Cristina ;
Snyder, James P. ;
LaVallee, Theresa M. ;
Giannakakou, Paraskevi .
CELL CYCLE, 2009, 8 (23) :3914-3924